Anti CD47 Drugs Market SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024 - 2031)

Anti CD47 Drugs Market is segmented By Target Disease Indication (Acute Myeloid Leukemias, Non-Hodgkin Lymphoma, Colorectal Cancers, Diffuse Large Bcell Lymphoma, Myelodysplastic Syndromes, Non-Small Cell Lung Cancers, Ovarian Epithelial Cancer, Oral Muscositis, Small Cell Lung Cancers), By Type of Molecule (Biologics, Small Molecules), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa). The report offers the value (in USD Billion) for the above-mentioned segments.

Anti CD47 Drugs Market is segmented By Target Disease Indication (Acute Myeloid Leukemias, Non-Hodgkin Lymphoma, Colorectal Cancers, Diffuse Large Bce....

Anti CD47 Drugs Market Leaders

Bristol Myers Squibb
ALX Oncology
Trillium Therapeutics
Innovent Biologics
Forty Seven

*Disclaimer: Major players are listed in no particular order.

Anti CD47 Drugs Market - Company List

Bristol Myers Squibb
ALX Oncology
Trillium Therapeutics
Innovent Biologics
Forty Seven
Abpro
Apmonia Therapeutics
Arch Oncology
Aurigene
EpicentRx
ImmuneOncia Therapeutics
ImmuneOnco Biopharmaceuticals
KAHR Medical
Light Chain Bioscience
Morphiex

Anti CD47 Drugs Market Report Snapshots

Buy Now